Lirentelimab - Allakos
Alternative Names: AK 002; AntolimabLatest Information Update: 31 Jan 2024
Price :
$50 *
At a glance
- Originator Johns Hopkins University School of Medicine
- Developer Allakos
- Class Anti-infectives; Anti-inflammatories; Antiallergics; Antiasthmatics; Antibodies; Antifibrotics; Eye disorder therapies; Food allergy immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Mast cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Chronic obstructive pulmonary disease; Chronic urticaria; Conjunctivitis; Eosinophilic gastroenteritis; Eosinophilic oesophagitis; Fibrosis; Keratoconjunctivitis; Systemic mastocytosis